News

A new indication for rivaroxaban (Xarelto) has been approved by FDA.

A survey from insuranceQuotes.com has surprising findings about open enrollment and the ACA.

Home non-invasive ventilation supports longer lives, fewer readmissions, and lower costs than other devices, based on findings of a KPMG study.

Managing psoriasis can be difficult for a variety of reasons. Here’s a look at the top six challenges that experts identified.

Philadelphia has the purest and cheapest heroin in the country and a long history of multigenerational heroin addicted families. Here’s what Independence Blue Cross is doing about it.

A Wamberg Genomic Advisors’ Cancer Survey has revealing findings from people dealing directly with cancer.

As lymphoma treatments become less cookie-cutter and more custom, the Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, shares how healthcare executives need to alter their approach to managing therapy regimens to increase cure rates and survivorship.

With healthcare being a key issue in the midterm elections, here are 11 things healthcare executives should keep in mind.

A new study was conducted to better understand the landscape of coverage of non-pharmacologic treatments for chronic pain among public and private insurers in the United States. Here’s what it found.

The launch of a new connected health platform will aid in management of diseases such as diabetes.

FDA approved a new antibiotic to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).

A new study linking attention-deficit hyperactivity disorder (ADHD) drugs and Parkinson’s disease could cause prescribers to re-think prescribing the medications.

Healthcare experts detail three policies that MCOs should keep a close eye on.

Innovative PBM performance-based pharmacy networks focus on reducing costs and Improving clinical outcomes

These technology solutions on the market can treat chronic pain, allowing patients to eliminate or decrease their dependence on opioid drugs.

Here are the top 3 new approvals from FDA.

Here are five of the most promising healthcare technologies that will make your healthcare organization in step with the future.

In the managed healthcare market, words like logical, predictable, or stable are seldom used anymore. Instead, for healthcare executives, disruption is the norm.

A new study from Health Care Cost Institute has revealing findings about employer-sponsored insurance plans.

Payers challenged a 2014 CMS Overpayment Rule and won. Here’s what healthcare executives should know.

A stepwise approach can be best. Here are seven rules to follow.

A Mayo Clinic study has surprising findings about how controlled substance agreements impact patients on long-term opioid therapy.

An Avalere analysis finds that this factor plays an important role in the era of value-based payment. Find out what it is.

While Teva Pharmaceutical’s new migraine prevention drug is unique, it faces competition from another major migraine treatment.

Pharmacy and healthcare experts cautiously praised the planned development of a fast-acting, better version of naloxone (Narcan), which is used to reverse the effects of opioid overdoses.

How would you define a specialty pharmaceutical? Chances are, it’s different from the way another healthcare executive would define them.

The hope is that more biosimilars will lead to more access and more affordable medications, but biosimilar uptake is lagging. Here’s why and how FDA hopes to fix it.